Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | MYOC | Q99972 | 1/20 | 0.77 |
| ▸ | TERT | O14746 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | SNCA | P37840 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8847553 | 1.00 | MAPT (0.77) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL30382983 | 1.00 | MAPT (0.77) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL25192703 | 0.87 | MAPT (1.00) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL31233153 | 0.87 | MAPT (1.00) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL4973168 | 0.87 | MAPT (1.00) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL5508056 | 0.87 | MAPT (1.00) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL22323624 | 0.87 | MAPT (0.59) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL22323623 | 0.87 | MAPT (0.59) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL22412626 | 0.86 | MAPT (0.75) | MAPTKMT2AKDM4EPTGS1PTGS2 | |
| SCHEMBL25200543 | 0.86 | MAPT (0.75) | MAPTKMT2AKDM4EPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-5610169-A | Pharmaceutical Composition containing slightly water-soluble drug | THE GREEN CROSS CORPORATION (JP) | 1997-03-11 | — | — | US | disclosed |
| US-5462951-A | Dissolved in a polyoxyethylene sorbitan fatty acid ester and adsorbed onto a porosity inorganic substance | THE GREEN CROSS CORPORATION (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0448091-A2 | Pharmaceutical composition containing slightly water-soluble drug | THE GREEN CROSS CORPORATION (JP) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885KMT2A 2792/4885KDM4E 1732/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885KMT2A 3188/4885KDM4E 2652/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885KMT2A 3188/4885KDM4E 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.